© 2021 MJH Life Sciences and OncLive. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
October 5th 2018
Although checkpoint-blocking antibodies dominate the anticancer immunotherapy field today, researchers are increasingly exploring the potential to leverage growing knowledge about tumor-infiltrating lymphocytes to develop new drugs.
October 2nd 2018
Less than 5 years after BTK inhibition was introduced in hematologic malignancies, the need for strategies to address primary and secondary mechanisms of resistance has emerged.